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Background: Oral bisphosphonates are commonly used to prevent / treat osteoporosis. However, bisphosphonate
treatment is not without risk and serious adverse effects, including upper gastrointestinal bleeding (UGIB) have
been described. We sought to determine if new users of bisphosphonate drugs were more likely to suffer a serious
UGIB within 120 days of drug initiation.
Methods: This was a population-based nested cohort study utilizing administrative healthcare data in British
Columbia, Canada. Community based individuals ≥ 65 years with a new prescription for a bisphosphonate between
1991 and 2007 were included. A multivariate logistic regression model was used to examine the relationship
between older age and the development of a serious UGIB within 120 days of new exposure to oral
bisphosphonate drugs.
Results: Within the exposure cohort (n = 26,223), 117 individuals had suffered a serious UGIB within 120 days of
incident bisphosphonate use. Cases tended to be > 80 years old, and were significantly more likely to have had a past
history of gastric ulcer disease, a remote history of serious UGIB, and had been dispensed proton pump inhibitor (PPI)
medications (p < 0.001 for all comparisons). After adjustment for confounding covariates, those > 80 years were more
than twice as likely to suffer a UGIB when compared to those ≤ 80 years (adjusted OR = 2.03; 95% CI 1.40–2.94). A past
history of serious UGIB was the strongest predictor of UGIB within 120 days of incident bisphosphonate use
(adjusted OR = 2.28; 95% CI = 1.29–4.03) followed by PPI use (adjusted OR = 2.04; 95% CI = 1.35–3.07). Males were 70%
more likely to suffer an UGIB compared to females (adjusted OR = 1.69; 95% CI = 1.05–2.72).
Conclusions: Upper GIB is a rare, but serious, side effect of bisphosphonate therapy more often afflicting older
individuals. At the same time, concern about potential rare adverse events should not discourage clinicians from
prescribing bisphosphonate drugs, particularly in older patients who have already sustained a fragility fracture. Clinicians
must remain cognizant of potential adverse events associated with bisphosphonate use and should routinely ask about
pre-existing GI disorders and concurrent medication history prior to prescribing these drugs.
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The routine management of osteoporosis should target
all aspects of the disease, including maximizing and
preserving bone mass and preventing future fractures
through pharmacotherapy and lifestyle modification
[1]. The mainstay of osteoporosis treatment includes
calcium and vitamin D, along with an antiresorptive
agent (usually a bisphosphonate drug) [1,2]. In addition to
osteoporosis treatment, bisphosphonate drugs are also
used for less common conditions such as Paget’s disease
of the bone and malignancy related bone pain and bone
loss [3]. Bisphosphonates have been shown to rapidly
reduce bone-remodeling, thus increasing bone mass
density, and are associated with the largest reduction
in fracture risk when compared to other therapies [4].
However, bisphosphonate treatment is not without risk
and serious adverse drug reactions (ADRs), including
osteonecrosis of the jaw [5], oral and gastric carcinomas
[6-8], atypical femur fractures [9,10], and upper gastro-
intestinal bleeding (UGIB), although infrequent, have
been described but remain controversial [11-15]. Drug
induced dysphagia, esophagitis, and gastric ulcers are the
most common of the gastrointestinal (GI) ADRs associated
with oral bisphosphonate therapy. Upper GI effects are
largely linked to improper drug administration regimes
(i.e. insufficient water intake and failing to sit upright
following medication ingestion) [15] and the local effects of
bisphosphonates on the esophagus or gastric mucosa. In
fact, ADRs, defined as any injury resulting from medication
use that occurs due to pharmacologic properties of the
drug [16], are thought to be the reason for bisphosphonate
discontinuation in up to 20% of subjects [17].
Although several observational studies have reported
on minor GI adverse effects such as nausea, dyspepsia,
and epigastric pain, few large population based studies have
assessed the more serious adverse events of drug-induced
acute UGIB. One large population based case–control
study utilized a Canadian population to compare the
risk of UGIB between users of bisphosphonates alone
and users of bisphosphonates and NSAIDS concurrently
[18]. This study by Etminan et al. utilized a previously
established community-based cohort of individuals who
had undergone a prior coronary revascularization pro-
cedure; of note, this population was highly selected,
and therefore may not necessarily be representative of
the general population. They found no evidence of an
increase in the risk of UGIB among current users of
bisphosphonate, but did find a two fold increase in risk
for concurrent users of bisphosphonates and NSAIDs.
Another population based study investigated the excess risk
of hospitalizations for UGIB associated with alendronate
use. These authors conducted a matched case control
study and found a higher unadjusted rate of UGIB for
bisphosphonate users; after controlling for confoundingvariables such as prior osteoporosis fractures, they
found no significant differences in risk between cases
and controls [19].
A different study, based on a Danish population, in-
vestigated the risk of esophageal and gastric events in a
group of older adults [20]. For their endpoint, these
authors did not distinguish between those developing
minor GI conditions such as esophagitis with those
suffering the more serious event of a UGIB. They mea-
sured the rates of adverse GI events both before and
after the initiation of various osteoporosis medications.
The authors found no difference as they discovered
that GI event rates were increased both before and
after initiation of the drugs. Other studies have focused
primarily on either daily versus weekly bisphosphonate
dosing (finding fewer GI events with weekly dosing) or
have compared the GI tolerability of two separate
bisphosphonate medications. For example, one such study
by Cadarette et al. compared the GI safety between weekly
doses alendronate and risedronate. These authors
found no important differences between the two weekly
preparations [21].
Objectives
Definitive evidence of a causal relationship between
bisphosphonate therapy and serious ADRs, particularly
UGIBs is lacking. Furthermore, there remain concerns
about the risks of long term treatment particularly
among older patients with increased co-morbidity. For
that reason, we sought to examine the risk of serious
UGIB among incident oral bisphosphonate users in British
Columbia (BC), Canada. Specifically, we sought to deter-
mine if community dwelling older adults (> 80 years), who
were new users of bisphosphonate drugs (incident users),
were more likely to suffer a serious UGIB within 120 days
of drug initiation in comparison to younger (≤ 80 years)
incident users of the same therapy.
Methods
Study design and data source
We performed a population-based retrospective nested
cohort analysis utilizing de-identified administrative
healthcare data derived from the British Columbia
Linked Health Database (BCLHD). This database
contained comprehensive healthcare utilization data
for nearly all residents of BC, Canada (population 4.1
million, 2006 Statistics Canada census data). The BCLHD,
which integrates health service records, population health
data, and census statistics, makes it possible to link
administrative records anonymously at the individual level
by using a unique personal health number (PHN). The
BCLHD has been used in numerous healthcare and health
services research projects since 1996; thus, this database is
well suited to explore clinical questions. Prior to accessing
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Research Ethics Board at the University of Alberta.
Identification of the study sample
We used a previously assembled cohort of all persons
aged ≥ 65 years who had suffered a fracture between
April 1, 1991 and March 31, 2002 (n = 81,870). Within
the fracture group, 63% had sustained a hip fracture,
17% an arm / wrist fracture, 9% a pelvic fracture, 7% a
vertebral fracture, and 4% had sustained a rib fracture.
In addition, a comparison group consisting of a random
sample (n = 142,077) of non-fracture subjects registered
in the BCLHD over the same time period were added to
the cohort for a total source cohort of 223,947 individual
patients. Follow-up of this population continued an
additional 5 years until March 31, 2007. As we focused
only on those prescribed bisphosphonates, the fracture
cohort was not separated from the comparison group
nor was it delineated in the analysis. The study group all
had continuous enrolment in the PharmaCare prescription
benefits plan (Fair PharmaCare or Plan B) during the study
index period. PharmaCare is BC’s public drug insurance
program that assists residents in paying for eligible
prescription drugs and certain medical supplies [22].
The PharmaCare dataset includes patient level prescription
drug expenditures for community dwelling individuals and
residents of licensed residential care facilities. Between 1991
and 2007 the population aged ≥ 65 years in the province
grew from approximately 428,088 to 616,804 [23].
From this initial cohort, we constructed a bisphosphonate
“exposure” cohort using PharmaCare data to identify all
incident users of bisphosphonate drugs; incident users were
defined as patients ≥ 65 years who had been dispensed an
oral bisphosphonate drug during the study index
period (n = 26,518 [11.8%]). As we were primarily
interested in ADRs associated with new users of the
drug, we excluded any person who had received an oral
bisphosphonate within the previous 365 days of the
index date (i.e. bisphosphonate wash-out period). Oral
bisphosphonate drugs available during the index period and
covered by the PharmaCare plan included alendronate
(Fosamax), etidronate (Didrocal), and risedronate (Actonel).
Although there are currently other manufacturers and
brand names for alendronate (the patent on aledronate
expired in 2008), Fosamax was the only formulation
available during the study index period as the only
manufacturers were the patent holders.
The index date was defined as the date of first claim
for an oral bisphosphonate prescription during the index
period. Gastrointestinal symptoms appear in similar
rates, regardless of the specific oral bisphosphonate or
dosing regimen; therefore, we included all available
bisphosphonate formulations regardless of whether the
dosing was daily or weekly [21,24].Identification of cases
To identify nested cases (those sustaining an UGIB
within 120 days of incident bisphosphonate use) within
the bisphosphonate exposure cohort, we then linked to the
Discharge Abstract Database (DAD) to identify patients
with a diagnosis of UGIB. The DAD contains demographic,
administrative, and clinical data for hospital discharges
(inpatient acute, chronic, and rehabilitation) and day
surgeries [25]. The data are collected per patient
admission and contain up to 16 diagnosis codes. We
included patients ≥ 65 years with a hospital admission
(primary, secondary, or other) for an acute UGIB occurring
within 120 days from the dispensation of an oral
bisphosphonate prescription (n = 412). We defined a
serious UGIB as those patients who had been admitted
to hospital with an acute and / or unspecified hemorrhage
and / or perforation of either a gastric, duodenal, peptic,
or gastrojejunal ulcer or an unspecified hemorrhage of the
gastrointestinal tract (See Additional file 1 for the specific
ICD-9 codes used). Rates of GI related adverse events tend
to be the highest in the first few months following the ini-
tiation of the therapy; thus, a 120 day time period was
deemed sufficient to capture the majority of adverse
events [26-29]. Oral bisphosphonates are dispensed in
100-day quantities under the PharmaCare plan; therefore,
patients will be considered at risk for 120 days after a
dispensed prescription. This time period allows for the
consumption of the prescription, subsequent early
refills (i.e. not beginning the prescription immediately
upon filling because the previous prescription of a medica-
tion other than a bisphosphonate was not complete), and
possible non-adherence (i.e. prescription lasting longer
than intended). Other researchers have used this approach
to analyze rare events associated with prescription drug
use with administrative data [21,30].
To identify additional cases of UGIB related deaths
(without hospitalization), we then linked to the BC Vital
Statistics death events registry (for cause of death). This
registry includes all deaths that occur within the province
[31]. Patients with a previous diagnosis of UGIB, requiring
hospitalization or related death, within 365 days prior
to the index date of drug dispensation were excluded
(n = 295) leaving 26,223 individual patients in the
exposure cohort of which 117 had sustained an UGIB.
As this was a prevalent controls design, those who had
been dispensed oral bisphosphonate therapy, but did
not suffer a UGIB or related death by the end of the study
period, acted as the internal control group (n = 26,106).
See Figure 1 for sample selection procedures.
Outcome measures and analysis
All analyses were stratified by UGIB status and age and
descriptive statistics were used to summarize the charac-
teristics of the population. We planned to firstly explore
Bisphosphonate “Exposure” Cohort
Those ≥ 65 years of age newly dispensed an 
oral bisphosphonate during the study index 
period – excluded those who were dispensed 
the drug within the previous 365 days
(n = 26,518)
UGIB = upper gastrointestinal bleed
Identify nested cases within the 
bisphosphonate cohort – those with a 
diagnosis of UGIB and UGIB related 
death within 120 days of drug index date
(n = 412)
Exclude – patients with 
previous diagnosis of UGIB 
within 365 days prior to 
index date of drug
(n = 295)
Outcome “case” group:
UGIB or UGIB related 
death
(n = 117)
Internal control group: 




Those ≥ 65 years with a fracture between 
April 1, 1991 and March 31, 2002 (n = 81,870) and a 
random sample (n = 142,077) of non-fracture subjects 
registered in the BCLHD over the same time period 
(n = 223,947)
Figure 1 Identification of the study sample. UGIB = upper gastrointestinal bleed.
Knopp-Sihota et al. BMC Geriatrics 2013, 13:36 Page 4 of 12
http://www.biomedcentral.com/1471-2318/13/36relationships between the dependent variable (UGIB within
120 days of incident oral bisphosphonate use), age group
(the main independent variable), and the covariates of sex,
co-morbidity, any past history of gastric ulcer disease,
past history of serious UGIB requiring hospitalization,
and concurrent use of prescription nonsteroidal anti-
inflammatory drugs (NSAIDs), antiplatelet / anticoagulation
medications, and the use of proton pump inhibitors (PPIs)
using Pearson’s chi square (χ2) statistics, with alpha (p) set
at 0.05 to determine the statistically significant differences
between groups. Where there were unexpected findings,
we planned to conduct a post hoc analysis to further
explore the relationships between variables. As this
was a population-based study, a sample size calculation
was not warranted.
To compare the incidence rates (IR) for UGIB between
age groups we calculated the person-time of exposure
based on the assumption that the exposure cohort were all
at risk (exposed) for 120 days post incident bisphosphonate
use. To compare the relative risk (RR) for UGIB amongincident bisphosphonate users (in the immediate 120 day
time period) with the general population, we used a popula-
tion rate for UGIB as 1 per 1,000 person-years [32,33].
Using univariate logistic regression techniques, we
initially assessed the unadjusted odds ratios (OR) and 95%
confidence intervals (CI) between the dependent variable
(UGIB within 120 days of incident oral bisphosphonate
use), age group (the main independent variable), and all co-
variates. Using the techniques described by Hosmer and
Lemeshow, we planned to include only those variables that
were statistically significant (p < 0.20) in the multivariate
analysis [34]. The co-morbidity (p = 0.57 to 0.49) and
anticoagulation (p = 0.85) variables were not statistically
significant; however, we considered both of these variables
to be clinically important so we included them in the initial
multivariate model (both were later removed from the
model as they continued to show no statistical significance).
See Table 1 for the unadjusted, univariate regression results.
For the multivariate analysis, we used the Enter procedure
in which all independent variables are entered in a single




n = 117 (0.4)
≤ 80 years n = 47 (40.2) > 80 years n = 70 (59.8)
Age (y)
≤ 80 47 - (reference)
> 80 - 70 2.08 (1.44, 3.01) 0.000
Sex c
Female 39 (83.0) 57 (81.4) (reference)
Male 8 (17.0) 13 (18.6) 1.72 (1.07, 2.76) 0.025
Comorbid conditions c
None 2 (4.3) 4 (5.7) (reference)
1 – 3 9 (19.1) 17 (24.3) 1.29 (0.51, 3.15) 0.571
4 - 6 28 (59.6) 38 (54.3) 1.61 (0.70, 3.71) 0.267
7 - 15 8 (17.0) 11 (15.7) 1.69 (0.55, 3.48) 0.487
Past history of gastric ulcer disease b
No 35 (74.5) 58 (82.9) (reference)
Yes 12 (25.5) 12 (17.1) 2.21 (1.41, 3.46) 0.001
Past history of serious GI bleeding b
No 41 (87.2) 62 (88.6) (reference)
Yes 6 (12.8) 8 (11.4) 2.79 (1.59, 4.90) 0.000
NSAIDs (oral) d
No concurrent use 42 (89.4) 65 (92.9) (reference)
Concurrent use 5 (10.6) 5 (7.1) 0.42 (0.22, 0.80) 0.009
Anti-platelet / anti- coagulant drugs (oral) c
No concurrent use 40 (85.1) 64 (91.4) (reference)
Concurrent use 7 (14.9) 6 (8.6) 0.85 (0.48, 1.51) 0.848
Proton pump inhibitor drugs (oral) b
No concurrent use 33 (70.2) 50 (71.4) (reference)
Concurrent use 14 (29.8) 20 (28.6) 2.03 (1.36, 3.03) 0.001
a Data are shown as number (percentage) unless otherwise indicated.
b p < 0.001.
c Not significant.
d p < 0.05.
CI = confidence interval; GI = gastrointestinal; NSAID = UGIB = upper gastrointestinal bleed.
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interaction between the main independent variables
(age group) and all other covariates. We pre-specified that
we would consider only interaction terms that achieved a
level of statistical significance of p < 0.10 [34].
We then checked for confounding of the variables that
were removed from the model; as none of the beta coef-
ficients changed by more than 15% we were satisfied
that neither of the variables were statistically significant
predictors of the dependent outcome nor confounders.
There were no statistically significant interactions between
the main independent variable (age group) and the
remaining variables; therefore, none of the interaction terms
were retained in the final model. The final multivariate
model included the variables: age, sex, past history of gastriculcer disease, past history of serious UGIB, concurrent use
of prescription NSAIDs and the use of PPIs. The adjusted
ORs were considered statistically significant if the 95% CI
did not include 1. All analyses were conducted using SPSS
version 19.0 (IBM SPSS Statistics).
Explanatory variables: covariates
Based on clinical relevance and known UGIB risk factors
identified in previous research [32,35-38], we planned to
control for the following potential confounders: age
(grouped as ≤ 80 years and > 80 years), sex (female, male),
remote past history (> 1 year prior) of serious UGIB
requiring hospital stay (ICD-9 codes 530–535 or 578
in the DAD file), past history of gastric ulcer disease
(ICD-9 code of 530–534 in the Medical Services Plan
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oral NSAIDs, and oral antiplatelet / anticoagulation
medications. Concurrent use of a PPI was also examined
as other researchers have used the use of PPIs as a marker
or proxy for the presence of preexisting GI disease. See
Additional file 2 for the specific medications we included
in the analysis.
To assess the prevalence of co-morbidity, a priori
we assembled a constellation of 15 chronic disease
diagnoses, which are often symptomatic and are thus
important in predicting morbidity and mortality.
Co-morbidity is defined as the co-existence of two
or more chronic conditions or impairments that
have an impact upon patient independence and survival
[39]. Specifically, the co-morbidities included in the
analysis were: cancer, cerebrovascular disease, diabetes,
cardiovascular disease, hypertension, osteoporosis,
osteoarthritis, rheumatoid arthritis, neurotic disorders,
depression / psychosis, incontinence, Parkinson’s disease,
chronic obstructive pulmonary disease, and asthma. The
diagnoses chosen were largely based on those identified in
other co-morbidity indices (i.e. The Charlson Index [40]
and Elixhauser’s method [41]) and have been used in
previous studies [42]. Co-morbidity was identified by
searching the MSP payment file to identify those
patients with at least two primary care visits for the
same diagnosis within the last two years of the study
period. The MSP is the province’s universal health
insurance program, and contains data on outpatient
services provided by fee for service practitioners. One
diagnosis code is reported per patient encounter; this
code is assumed to be the primary diagnosis or reason
for the visit or service [43]. In order to compare co-
morbidity between subjects, we simply added the number
of diagnoses. This “disease counting” approach is less
complex and studies have shown them to be as effective
(if not more effective) as other more complex measure-
ments in predicting and controlling for co-morbidity such
as the Charlson Index [44-47].
Results
Study population
After exclusion criteria were applied, we identified
26,223 individual patients in the exposure cohort. The
mean age of the sample was 78.8 years (SD 6.9; range
65–104 years), and 88% of the subjects were female.
The majority of the cohort had between 4 and 6 co-morbid
conditions (51%), 10% had a past medical history of gastric
ulcer disease, 5% had a remote history of serious UGIB,
18% used NSAIDs, 13% used antiplatelet / anticoagulant
prescriptions drugs, and 17% used PPIs.
Within the exposure cohort, 117 (0.4%) individual
patients had suffered a serious UGIB (116 requiring
hospitalization and one death) within 120 days of incidentbisphosphonate use; the remaining 26,106, acted as the
internal control group. Those who developed an UGIB
(the 117 cases) tended to be > 80 years old (60%), and
when compared to those who did not suffer a UGIB,
they were significantly more likely to have had a past
history of gastric ulcer disease (21% vs. 11%), a remote
history of serious UGIB (12% vs. 5%), and had been dis-
pensed PPI medications (29% vs. 17%) (all were p < 0.001).
Cases were less likely to have been dispensed NSAIDs com-
pared to controls (9% vs. 18%; p < 0.05). There were no
statistical differences in sex, level of co-morbidity, or use of
antiplatelet / anticoagulant prescriptions drugs between
groups. See Table 2 for characteristics of the exposure
cohort stratified by UGIB status.
We explored a number of post hoc relationships between
variables of interest. Those with greater co-morbidity were
significantly more likely to have been dispensed a NSAID
and there was an inverse relationship between NSAID use
and the past history of gastric ulcer disease. There were
significant positive relationships between PPI use and a past
history of gastric ulcer disease and between PPI use and a
past history of a serious UGIB.Incidence of UGIB
Assuming those in the bisphosphonate exposure cohort
were at risk for 120 days, we calculated an overall RR of
approximately 14 per 1,000 person-years for UGIB
within 120 days of incident bisphosphonate prescription.
When stratified by age, those patients > 80 years (RR = 19)
had more than two times the incidence of UGIB compared
to those ≤ 80 years (RR = 9). The corresponding absolute
risk (AR) increase was 13 per 1,000 per years. See Table 3
for crude IRs.Factors associated with UGIB: logistic regression analysis
A past history of serious UGIB was the strongest predictor
of UGIB within 120 days of incident bisphosphonate use
(adjusted OR = 2.28; 95% CI = 1.29–4.03). The next
strongest predictor of UGIB was the concurrent use of
PPI medications. In comparison to those who were not
concurrently dispensed a PPI medication, patients with
a PPI were significantly more likely to suffer an UGIB
within 120 days post initiation bisphosphonate drug
(adjusted OR = 2.04; 95% CI = 1.35–3.07). Other statisti-
cally significant predictors of UGIB included age > 80 years
(adjusted OR = 2.03; 95% CI = 1.40–2.94), a past history
of gastric ulcer disease (adjusted OR = 1.90; 95% CI =
1.21–3.01), and male sex (adjusted OR = 1.69; 95% CI =
1.05–2.72). The use of prescription NSAIDs was found to
be a significant negative predictor of UGIB (adjusted OR =
0.41; 95% CI = 0.21–0.80). See Table 1 for the unadjusted
ORs and Table 4 for factors (the adjusted ORs) predicting
UGIB within 120 days of incident bisphosphonate use.
Table 2 Characteristics of bisphosphonate exposure cohort stratified by upper gastrointestinal bleeding status a
UGIB No UGIB Total
n = 117 (0.4) n = 26 106 (99.6) N = 26 223
Age (y) b
≤ 80 47 (40.2) 15,213 (58.3) 15,260 (58.2)
> 80 70 (59.8) 10,893 (41.7) 10,963 (41.8)
mean ± SD 81.8 ± 6.9 78.8 ± 6.9 78.8 ± 6.9
Sex c
Female 96 (82.1) 23,030 (88.2) 23,126 (88.2)
Male 21 (17.9) 2,934 (11.2) 2,955 (11.3)
Unknown 0 142 (0.5) 142 (0.5)
Comorbid conditions c
None 6 (5.1) 1,936 (7.4) 1,942 (7.4)
1 – 3 26 (22.2) 6,490 (24.9) 6,516 (24.8)
4 - 6 66 (56.4) 13,256 (50.8) 13,322 (50.8)
7 - 15 19 (16.2) 4,424 (16.9) 4,443 (16.9)
mean ± SD 4.77 ± 2.1 4.41 ± 2.2 4.41 ± 2.2
Comorbid conditions (by diagnosis)
Cancer c 44 (37.6) 9,056 (34.7) 9,100 (34.7)
Cerebrovascular disease c 30 (25.6) 5,324 (20.4) 5,354 (20.4)
Diabetes c 16 (13.7) 4,269 (16.4) 4,285 (16.3)
Cardiovascular disease b 91 (77.8) 16,542 (63.4) 16,633 (63.4)
Hypertension c 84 (71.8) 17,437 (66.8) 17,521 (66.8)
Osteoporosis c 27 (23.1) 7,354 (28.2) 7,381 (28.1)
Osteoarthritis c 66 (56.4) 14,954 (57.3) 15,020 (57.3)
Rheumatoid arthritis c 11 (9.4) 3,481 (13.3) 3,492 (13.3)
Neurotic disorder c 52 (44.4) 9,941 (38.1) 9,993 (38.1)
Depression / psychosis c 60 (51.3) 12,403 (47.5) 12,463 (47.5)
Dementia c 27 (23.1) 5,050 (19.3) 5,077 (19.4)
Incontinence c 48 (41.0) 9,473 (36.3) 9,521 (36.3)
Parkinson’s c 2 (1.7) 835 (3.2) 837 (3.2)
COPD c 38 (32.5) 7,910 (30.3) 7,948 (30.3)
Asthma c 16 (13.7) 3,533 (13.5) 3,549 (13.5)
Past history of gastric ulcer disease b
No 93 (79.5) 23,374 (89.5) 23,467 (89.5)
Yes 24 (20.5) 2,732 (10.5) 2,756 (10.5)
Past history of serious GI bleeding(requiring hospital stay) b
No 103 (88.0) 24,895 (95.4) 24,998 (95.3)
Yes 14 (12.0) 1,211 (4.6) 1,225 (4.7)
NSAIDs (oral) d
No concurrent use 107 ( 91.5) 21,342 (81.8) 21,449 (81.8)
Concurrent use 10 (8.5) 4,764 (18.2) 4,774 (18.2)
Anti-platelet / anti-coagulantprescription drugs (oral) c
No concurrent use 104 (88.9) 22,751 (87.1) 22,855 (87.2)
Concurrent use 13 (11.1) 3,355 (12.9) 3,368 (12.8)
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Table 2 Characteristics of bisphosphonate exposure cohort stratified by upper gastrointestinal bleeding status a
(Continued)
Proton pump inhibitors b
No concurrent use 83 (70.9) 21,725 (83.2) 21,808 (83.2)
Concurrent use 34 (29.1) 4,381 (16.8) 4,415 (16.8)
a Data are shown as number (percentage) unless otherwise indicated.
b p < 0.001.
c Not significant.
d p < 0.05.
GI = gastrointestinal; NSAID = Non-steroidal anti-inflammatory drug; UGIB = upper gastrointestinal bleed.
Table 4 Logistic regression model: factors predicting
gastrointestinal bleeding within 120 days of incident
bisphosphonate use
Variable Adjusted odds ratio (95% CI) p -Value
Constant 0.002 0.000
Age (y)
≤ 80 1 (reference)
> 80 2.03 (1.40, 2.94) 0.000
Sex
Female 1 (reference)
Male 1.69 (1.05, 2.72) 0.030
Past history of gastric ulcer disease
No 1 (reference)
Yes 1.90 (1.21, 3.01) 0.006
Past history of serious GI bleeding
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For many older adults with a diagnosis of osteoporosis,
oral bisphosphonate drugs are the first line of treatment.
While these drugs are typically safe, there have been reports
of serious adverse events. In this population-based nested
cohort study, we identified subjects in a Canadian province
with universal health care coverage, who were newly
dispensed a bisphosphonate drug. Although we found a
relatively low rate of UGIBs overall, only 0.4% of the
exposure cohort developing this rare event, older patients
(> 80 years) were significantly more often affected.
Using logistic regression techniques, we found that
older age was an independent risk factor for developing
an UGIB within 120 days post bisphosphonate treatment;
this relationship remained after controlling for sex, history
of gastric ulcer disease, history of serious UGIB, NSAID,
and PPI use. Regardless of age, patients who were male,
had a past history of gastric ulcer, a more remote UGIB
history, and used a PPI, were more likely to suffer a UGIB
post bisphosphonate use. Interestingly, patients who had
been dispensed NSAIDs concurrently were less likely to
develop a UGIB within 120 days of bisphosphonate use.
Age, sex, and risk of UGIB
The incidence of UGIB (within 120 days of incident
bisphosphonate use) was much higher for older subjects;
in fact, patients > 80 years of age developed an UGIB two
times more often when compared to those ≤ 80 years. This
finding is congruent with UGIB (from any cause) in the
general population where advanced age has consistently
been identified as a risk factor for the increased incidence
of UGIB and related mortality [38]. While we recognize
that older adults have multiple factors influencing their risk
of GI bleeding, UGIB is thought primarily to be related toTable 3 Crude incidence rates of upper gastrointestinal
bleeding within 120 days of incident bisphosphonate
drug prescription
≤ 80 years > 80 years Total
Number of UGIB events 47 70 117
Person-time at risk (y) 5,017 3,604 8,621
Incidence rate a 9.4 19.4 13.6
a Incidence rate (per 1 000 person-years).
UGIB = upper gastrointestinal bleed.increased co-morbidity and the use of multiple medications
in the older age group [37]. Although we were unable to
control for total medication counts per patient in our study,
we postulate that the increased co-morbidity in the older
group corresponded to an increase in medication use which
potentially contributed to greater UGIB risk. Additional
factors identified by other researchers include inactivity and
disability, both of which have been associated with a higher
risk of GI bleeding in older adults [37,48]. Others have
attributed the increased incidence to the increased use
of NSAIDS in older adults, who are at greater risk of GI
toxicity from these agents, as well as a higher prevalence
of Helicobacter pylori and gastroesophageal reflux
disease [49,50]. Peptic ulcer disease is not only strongly
associated with Helicobacter pylori infection and more
common in older adults but is also well known as theNo 1 (reference)
Yes 2.28 (1.29, 4.03) 0.005
NSAIDs (oral)
No concurrent use 1 (reference)
Concurrent use 0.41 (0.21, 0.80) 0.008
Proton pump inhibitor drugs (oral)
No concurrent use 1 (reference)
Concurrent use 2.04 (1.35, 3.07) 0.001
CI = confidence interval; GI = gastrointestinal; NSAID = Non-steroidal
anti-inflammatory drug; UGIB = upper gastrointestinal bleed.
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ulcer disease was a strong independent predictor of UGIB;
specifically, those with a past history of gastric ulcer
disease were 90% more likely to develop an UGIB
(within 120 days of incident bisphosphonate use) than
those with no history of the disease.
In our study, we were concerned primarily with
bisphosphonate medications and their association with
UGIB in an older population. Esophagitis and gastropathy,
described as mucosal injury to the esophagus and
stomach respectively, can be caused by drugs such as
bisphosphonates that are known to cause local effects
on both areas of the GI tract [15]. Although overt
UGIB is an uncommon manifestation of esophagitis or
gastropathy, these lesions are implicated as bleeding
sources more frequently in the older adult, especially
those 80 years and older [51].
We found that regardless of age, males had an approxi-
mately 70% increased risk of hospitalization for UGIB than
females. This is consistent with previous studies, who have
found approximately a two-fold increase in the incidence of
UGIB, from any cause, in males than in females; however,
mortality rates are similar in both sexes [32,52]. In our
study this was not unexpected as the male group was also
found to have significantly more co-morbid disease, notably
cardiovascular disease, and were more likely to have a past
medical history of gastric ulcer disease both of which are
associated with an increased risk of UGIB.
NSAIDs, PPIs, and risk of UGIB
Many studies, of various designs, have focused on NSAID
use in relation to UGIBs; for the most part, findings over
the last 15 years suggest that current users of NSAIDS have
at least a 3 to 5 fold increased risk of UGIB [53]. Contrary
to these results, in our study we found that a prescription
for a NSAID was the strongest negative predictor of UGIB;
those who had been dispensed NSAIDs were two and a
half times less likely to suffer a UGIB within 120 days of
incident bisphosphonate use. Because of the known GI side
effects associated with NSAID use, we initially speculated
that perhaps patients, who were prescribed a NSAID, were
healthier patients with fewer co-morbid conditions, thus
less likely to develop a UGIB. We found that those with
greater co-morbidities were significantly more likely to
be dispensed a NSAID drug; therefore, the notion that
those prescribed a NSAID were healthier did not stand.
We did find an inverse relationship between NSAID
use and past history of gastric ulcer disease; those with
a gastric ulcer were less likely to have been dispensed
a NSAID. For that reason, we postulated that the
“protective” effect of NSAIDs may stem from their
use in patients who do not have a history of gastric
ulcer thus making users of NSAIDs perhaps less likely
to develop a UGIB. The clinical significance of thisfinding, however, is unclear and caution in the inter-
pretation of this finding is thus warranted.
We also found that those patients who had been
dispensed a PPI medication were two times as likely to
develop a UGIB post incident bisphosphonate use. As we
used the prescription of a PPI as a proxy for the presence
of GI disease, this finding was expected. Those who were at
an increased risk, or who have already developed GI
disease, are often prescribed drug therapy with either a
histamine-2 (H2)–receptor antagonist (typically available as
over the counter medications) or a PPI in order to provide
mucosal protection [54]. In other words, those patients
using a bisphosphonate and a PPI likely had a greater
underlying risk of an adverse GI event compared to those
persons using a bisphosphonate alone; this would account
for the observed increase in UGIB risk for concurrent users
of the drugs [19]. This was confirmed during post hoc
analysis where we found significant positive relationship
between PPI use and both a past history of gastric ulcer
disease and past serious UGIB.
Comparison to previous research
Although a number of randomized controlled trials (RCTs)
have reported higher rates of upper GI tract minor irrita-
tions in treatment groups (although not reaching statistical
significance), there have been no reports of more serious
upper GI tract adverse events such as UGIB [55-57].
RCTs typically follow a smaller group of highly selected
individuals for a relatively short period of time and are
designed primarily to investigate the fracture prevention
efficacy of bisphosphonates. Unfortunately, there are
few previous population based studies investigating the
risk of UGIB associated with bisphosphonate drugs to
compare our study results to [18-21].
Limitations
This study, as with other studies based solely on adminis-
trative data, has some limitations that must be recognized.
First, bisphosphonates are not only prescribed for the
prevention and treatment of osteoporosis, but also for
the treatment of certain malignancies and related malig-
nancy complications as well as other serious conditions
such as Paget’s disease of the bone. As we exclusively
examined oral bisphosphonate preparations, we can be
fairly certain that these drugs were not used to treat a
malignancy or related complication such as hypercalcemia
as these conditions are primarily treated with intravenous
bisphosphonate infusions. Furthermore, a diagnosis of
Paget’s disease is relatively rare (in comparison to a
diagnosis of osteoporosis); moreover, we were interested
in adverse events associated with new bisphosphonate use
and as we controlled for co-morbidity, we did not think
the primary therapeutic use of the drug would have
changed the results of our study.
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dispensation of bisphosphonate drugs and may not be
an accurate reflection of actual drug consumption
rates; therefore, we may have overestimated the use of
bisphosphonates and perhaps have then underestimated
UGIBs related to the new use of the drug (non-differential
misclassification). This type of misclassification of exposure
would bias the effect measure toward an apparent null
effect. Third, due to the claims-based nature of the dataset,
information related to other potentially confounding
variables could not be assessed or controlled for. For
example, we lacked data on other factors known to be
related to UGIBs such as smoking and alcohol consump-
tion, the use of over the counter medications such as
NSAIDs (i.e. ibuprofen) and ASA, and the presence of un-
diagnosed helicobacter pylori infections [32,58]. Although
the inclusion of these variables may have provided a more
inclusive description of potential UGIB predictors, we do
not believe that controlling for these variables would have
altered the results of this study.
Thirdly, we based the outcome diagnosis of UGIB
exclusively on discharge abstract coding and have no
way of knowing if endoscopy was done and if done, where
in fact the GI bleeding originated from (esophagus vs.
stomach). We attempted to overcome this limitation by
only including those patients who were diagnosed with a
“serious” bleed; therefore, we are confident that diagnoses
were confirmed in the clinical setting by endoscopy.
Lastly, we would be remiss if we did not acknowledge
that the relationship between bisphosphonates and
UGIBs may also be complicated by the known fact of an
already increased prevalence of GI tract symptoms
among older adults [59]. In our study, we did not find
differences in co-morbidity between those who developed
a UGIB and those who did not. We did find that those
who developed a UGIB were more likely to both have a
concurrent past diagnosis of gastric ulcer disease as well
as a remote history of UGIB. Taken together, this may
have accounted for some of the decrease in observed risk
in the group who did not develop a UGIB - even after
controlling for these variables as confounders.
The strengths of this study include its population-based
design, a large sample size, and its use of detailed data made
possible by the use of a comprehensive linkable dataset
including clinical and prescription drug information of
most residents in the province. To our knowledge, this is
one of the first comprehensive, population based studies of
UGIB incidence associated with new oral bisphosphonate
use. We used a strict case definition of UGIB, which has
been previously validated; this strategy for identifying cases
of UGIB (a rare event) was broad, reducing the likelihood
that cases were missed [60]. In addition, our study used a
co-morbidity index that had been previously validated with
the population and used sophisticated statistical analysis tocontrol for potentially confounding variables. Given the
longitudinal nature of the data, it was also possible to
examine drug use as both an exposure (bisphosphonate)
and an end-point (UGIB) thereby having the advantage of
enough accumulated person-time of bisphosphonate
exposure for detection of more rare GI associated adverse
events. Taken together, these factors ought to contribute
to a reliable estimate of the ORs for UGIBs within 120 days
of incident bisphosphonate use.
Conclusion
Upper GIB is a rare, but serious, side effect of
bisphosphonate therapy with older patients being affected
more often than younger ones. In our study, those incident
users of oral bisphosphonate drugs aged > 80 years had a
two-fold increase in serious UGIB within 120 days of new
drug use. Unfortunately, osteoporosis related fracture risk
also increases substantially with age and those older adults
are at a much higher risk of morbidity and mortality
related to fractures. Concern about potential rare adverse
events should not discourage clinicians from prescribing
bisphosphonate drugs when there is a high risk of fracture,
particularly in older patients many of who have already
sustained a fragility fracture. Although evidence of a defini-
tive causal relationship between bisphosphonate therapy
and serious adverse events such as UGIB is lacking, clini-
cians need to remain cognizant of potential adverse events
associated with bisphosphonate use and should routinely
ask patients about pre-existing GI disorders and concurrent
medication history prior to prescribing these drugs.
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